Asset

  • No.

    120

  • Asset Title

    A Novel Inhibitor Targeting Matrix Accumulation in Cancer

  • Organization

    Max-Planck Innovation

  • Product Type

    Peptide

  • Therapeutic Area

    Oncology

  • Development Stage

  • Technical Summary

    Scientists have identified a unique cyclic molecule that diminishes extracellular matrix production thereby reducing tumor growth in cancer with no toxicity. Our scientists have validated the reduction of tumor growth in the presence of the molecule in two distinct models: breast cancer and melanoma.

     

    • The present invention relates to peptides that inhibit overproduction and/or excess accumulation of extracellular matrix in an organ or tissue.
    • The inventive peptides have the general sequence Xa-Leu-Gln-Gly-Xb (SEQ ID NO: 1), wherein Xa is selected from Pro-Gly, Gly and Ac-Gly and Xb is selected from Glu and Glu-NH2, and are able of inhibit overproduction and excess accumulation of extracellular matrix in an organ or tissue both as linear peptides and as cyclic peptides.
    • In particular the peptides disclosed herein can be used for treating fibrotic conditions characterized by an excess accumulation of extracellular matrix such as liver fibrosis, cirrhosis of the liver, lung fibrosis, chronic respiratory failure, cardiac fibrosis, ischemic heart disease, heart failure, diabetic nephropathy, glomerulonephritis, myelofibrosis, and various types of cancers such as breast cancer, uterus cancer, prostate cancer, pancreas cancer, colon cancer, skin cancer, blood cell cancers, cancers of the central nervous system, fibroids, fibroma, fibroadenomas and fibrosarcomas.

  • Patent

    WO2021018923A1
    US20220267378A1
    EP3996694A1
    CN114364691A
    JP2022543227A

  • Publication

  • Attachment

TOP